Recently, our group published a study describing US28-mediated activation of RhoA to enhance emergence out of latent infection and that pharmacologic inhibition of US28-mediated RhoA signaling blocks viral reactivation in vitro and in vivo (39). The gene discussed is RHOA; the disease is disease arising from reactivation of latent virus.